AARD aardvarktherapeutics.com Net earnings per share for the last 12 months

The rolling trailing twelve-month earnings per share accounts for R&D expenses and the anticipation of clinical trial results, with the -3.33 value serving as the target level. Aardvark Therapeutics Inc (AARD) possesses a scientific reputation in the treatment of obesity. The company's revenues rely on future sales of drugs for patients with Prader-Willi syndrome through government funds and insurance systems.
Analytical breakdowns and data insights for company Aardvark Pharma (AARD)

Analyzing the 12-month net income per share chart allows for an assessment of the management efficiency of the innovative biotech asset Aardvark Therapeutics Inc (AARD) within the metabolic disorder therapy segment. This indicator reflects the final income distributed per share, enabling investors to evaluate the sustainability of the business model and the financial strength of Aardvark Therapeutics Inc (AARD) through profit dynamics amidst ongoing clinical trials.